siRNA Delivery to the Lung: What’s New?

Related Articles

siRNA Delivery to the Lung: What’s New?

Adv Drug Deliv Rev. 2014 Jun 4;

Authors: Merkel OM, Rubinstein I, Kissel T

Abstract
RNA interference (RNAi) has been thought of as the general answer to many unmet medical needs. After the first success stories, it soon became obvious that short interfering RNA (siRNA) is not suitable for systemic administration due to its poor pharmacokinetics. Therefore local administration routes have been adopted for more successful in vivo RNAi. This paper reviews nucleic acid modifications, nanocarrier chemistry, animal models used in successful pulmonary siRNA delivery, as well as clinical translation approaches. We summarize what has been published recently and conclude with the potential problems that may still hamper the efficient clinical application of RNAi in the lung.

PMID: 24907426 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Getting Effective Delivery from Your Asthma Inhaler: What Parents of … – Seaside Courier

Getting Effective Delivery from Your Asthma Inhaler: What Parents of
Seaside Courier
(BPT) – Did you know that Asthma affects approximately 26 million Americans, including 7.1 million children? May is Asthma and Allergy Awareness month and the perfect time to remind parents of asthmatics about the importance of making sure their child

and more »

View full post on asthma – Google News

Getting Effective Delivery from Your Asthma Inhaler: What Parents of … – ScoopSanDiego.com

Getting Effective Delivery from Your Asthma Inhaler: What Parents of
ScoopSanDiego.com
(BPT) – Did you know that Asthma affects approximately 26 million Americans, including 7.1 million children? May is Asthma and Allergy Awareness month and the perfect time to remind parents of asthmatics about the importance of making sure their child

and more »

View full post on asthma – Google News

New Manufacturing Method Improves Drug Delivery of Asthma Inhalers – Pharmaceutical Technology Magazine (blog)

New Manufacturing Method Improves Drug Delivery of Asthma Inhalers
Pharmaceutical Technology Magazine (blog)
A chemical engineering team from Monash University in Australia developed a method to manufacture ultrafine particles that will improve the consistency and efficiency of drugs used in metered-dose inhalers to treat asthma, the University announced in a 

View full post on asthma – Google News

On-off pulsed oral drug-delivery systems: a possible tool for drug delivery in chronotherapy.

Related Articles

On-off pulsed oral drug-delivery systems: a possible tool for drug delivery in chronotherapy.

Ther Deliv. 2011 Sep;2(9):1199-214

Authors: Tran TH, Lee BJ

Abstract
Circadian rhythms regulate most body functions and are important factors to consider when administering drugs. The existence of circadian rhythms in nature and their influences on human biological systems have given rise to the concept of chronotherapy, which is the science of delivering drugs in a synchronized manner with the rhythm-dependent circadian variation inherent in the human body. The safety and efficacy of a drug can be improved by matching the peak plasma concentration during a 24 h period of the rhythms. An on-off pulsed (pulsatile or time-controlled) release drug-delivery system offers rapid and transient release; stepwise release; and the sustained release of a certain amount of drug within a short time period after a predetermined off-release period according to the circadian rhythm of disease states. These systems deliver the drug at the right time and at an appropriate dosage and are the best approach for chronotherapy. These systems show promise for the optimal therapy of chronic diseases such as asthma, hypertension, myocardial infarction and arthritis, which show a circadian dependency. Various technologies have been adopted to mimic circadian rhythms in physiological functions and diseases. This review focuses on the basic concept of circadian rhythm, chronotherapy and recent advances in the development of on-off pulsed oral drug-delivery systems for optimal therapy.

PMID: 22833913 [PubMed – in process]

View full post on pubmed: asthma